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Abstract 
Background: Sensitive and glucantime (MA) resistance Leishmania tropica are re-
ferred to those isolates, which are responsive, or non-responsive to one or two full 
courses of treatment by MA systematically and/or intra-lesionally, respectively. In 
this study, we evaluated the antileishmanial activity of biogenic selenium nanoparti-
cles (Se NPs) alone and in combination with MA against sensitive and glucantime-
resistant L. tropica on in vitro model.  
Methods: The Se NPs were synthesized by employing the Bacillus sp. MSh-1. The 
antileishmanial effects of Se NPs alone and in combination with MA on pro-
mastigote and amastigote stages of sensitive and glucantime-resistant L. tropica 
strains have been investigated using a colorimetric MTT assay and in a macrophage 
model. In addition hemolytic activity in type O+ human red blood cells and infec-
tivity rate of the promastigotes before and after treatment with the Se NPs was 
evaluated.  
Results: In the promastigote stage, various concentrations of Se NPs significantly 
inhibited (P<0.05) the growth of promastigotes of both strains in a dose-dependent 
manner. Similarly, Se NPs especially in combination with MA significantly reduced 
the mean number of amastigotes of both strains in each macrophage. Se NPs 
showed no hemolytic effect on human RBCs at low concentrations. Moreover, in-
fection rate of macrophages by promastigotes significantly (P<0.05) was reduced 
when promastigotes pre-treated with Se NPs.  
Conclusion: The findings of this study suggest a first step in the search of Se 
NPs as a new antileishmanial agent. Further experiments are needed to investigate 
antileishmanial effects of biogenic Se NPs on L. tropica using a clinical setting. 
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Introduction 
 
eishmaniasis is one of the most im-
portant public health problems in 
tropical and sub-tropical countries. It 
is endemic in 98 countries and territories, af-
fecting 12 million people and approximately 
threatens 350 million, worldwide (1). It consists 
several different presentations including cutane-
ous, mucocutaneous and visceral forms. In Iran, 
there are two epidemiological forms of cutane-
ous leishmaniasis (CL); Anthroponotic CL 
(ACL) and zoonotic CL (ZCL) caused by Leish-
mania tropica and L. major, respectively (2, 3).  
At present, because there is not any effective 
vaccine; the effective control approach is 
prompt detection of the cases and early treat-
ment against leishmaniasis (4, 5). Although, 
antimonial compounds such as meglumine 
antimoniate have been used as the treatment 
of choice, resistance has frequently been re-
ported for L. tropica and L. donovani, the two 
Old World anthroponotic leishmaniases for 
many years (6-8). These species have devel-
oped resistance as reported from Africa, In-
dian sub-continent, South-east Asia particu-
larly Iran (1). This problem indicates the ur-
gent needs for development of new drugs or 
combination therapy for treatment of CL. 
However; extensive efforts have also been 
made to promote combination therapy of 
available drugs including verapamil, imiquimod 
and allopurinol that revealed synergistic effects 
with MA in the treatment of CL (9-11).  
Selenium (Se) is a trace element of funda-
mental importance to human health. It is a 
component of selenoproteins, some of which 
have important enzymatic functions (12). Se-
lenium has been used in various medical ther-
apies such as cancer prevention including lung, 
esophagus, prostate and gastric-cardiac can-
cers, antiviral activities and antioxidant effects 
(13-15). Moreover, Se has additional important 
health activities relevant to the immune re-
sponse and successful reproduction (15). It 
has currently been demonstrated that nanopar-
ticles (NPs) due to their large surface-volume 
ratio show various unique properties such as 
enhancing interactions with biological mole-
cules and microorganisms. NPs are also able to 
enter cells more frequently than other particles 
(16). NPs particularly Se NPs can effectively 
inhibit the growth of some bacteria such as 
Staphylococcus aureus and pathogenic Escherichia 
coli (16, 17). In addition, Se NPs significantly 
inhibited the growth of Echinococcus granulosus 
protoscoleces and L. major on in vitro and in vivo 
model (18, 19).  
In this study, we synthesized the biogenic Se 
NPs by employing the Bacillus sp. MSh-1 as a 
potent bacterium in selenium reduction. In the 
next step, to separate and purify Se NPs from 
the whole-cell lysate, we used a liquid-liquid 
two-phase partitioning method. After charac-
terization of the purified Se NPs, the effect of 
Se NPs on L. tropica promastigotes was stud-
ied by MTT assay. Finally, the antileishmanial 
activity of NPs on clinical stage was evaluated 
in an amastigote-macrophage model. 
 
Materials and Methods 
 
Chemicals 
Meglumine antimoniate (MA, Glucantime) 
as control drug was prepared from Rhône, 
Poulenc, France. Penicillin and streptomycin 
were obtained from Alborz Pharmacy, Karaj, 
Iran and were stored at room temperature 
(25°C) until testing. MTT powder [3-(4.5-
dimethylthiazol-2-yl)-2.5-diphenyl tetrazolium 
bromide)], fetal calf serum (FCS) and RPMI-
1640 medium with L-glutamine were pur-
chased from Sigma-Aldrich, St Louis, MO. 
Selenium dioxide (SeO2), nutrient broth, nutri-
ent agar, n-octyl alcohol, sodium dodecyl sul-
fate (SDS) and Tris base were purchased from 
Merck Chemicals (Germany). All other chemi-
cals and solvents were of analytical grade. The 
microorganism used in this study was identi-
fied as Bacillus sp. MSh-1 by the methods de-
scribed earlier (12). The organism was contin-
uously maintained on nutrient agar plates 
L 
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complemented with 1.26 mM SeO2 using con-
tinuous sub-culturing every 14 days. 
 
Biosynthesis and characterization of the 
Se NPs  
Se NPs were prepared according to the 
method described elsewhere (12). Briefly, a 
sterile nutrient broth (NB) medium was sup-
plemented with the Se+4 ions (100 mg/L; 
equal to 1.26 mM SeO2 solution) and 100 mL 
of this medium was transferred to a 500-mL 
Erlenmeyer flask. The medium was inoculated 
with 1 mL of the fresh inoculums (OD600, 0.1) 
of Bacillus species MSh-1 and was incubated 
aerobically at 30°C in a shaker incubator (150 
rpm). After 14 h, the bacterial cells and Se 
NPs were removed from the culture medium 
by using centrifugation at 4000 g for 10 min. 
The pellets were washed with 0.9% NaCl solu-
tion using centrifugation, transferred to a mor-
tar and then it was frozen by adding liquid ni-
trogen and was then disrupted by a pestle. The 
resulting slurry was ultrasonicated at 100 W 
for 5 min and washed three times by sequen-
tial centrifugation (10000 g for 5 min), with a 
1.5 M Tris-HCl buffer (pH 8.3) containing 1% 
SDS and deionized water. The next step in-
volved extracting and purifying the Se NPs 
through an organic-aqueous partitioning sys-
tem (n-octyl alcohol-water). For transmission 
electron microscopy, an aqueous suspension 
containing the Se NPs was dispersed ultrason-
ically, and a drop of the suspension was placed 
on carbon-coated copper TEM (transmission 
electron microscope) grids and dried under an 
IR lamp. The crystalline structure of the Se 
NPs was evaluated by the X-ray diffraction 
(XRD) technique using an X-ray diffractome-
ter (Philips PW1710) with CuKα radiation (λ 
= 1.5405 Å) over a scanning range of Bragg 
angles from 20 to 80°C. 
 
Parasite strains and culture  
Glucantime-resistant strain of L. tropica was 
prepared from a CL patient in Bam, south-
eastern Kerman province of Iran. This isolate 
was identified by nested-PCR as L. tropica and 
further determined by conventional PCR for 
MDR1 gene (8). Subsequently the DNA ex-
tract was sequenced and recorded in Gen 
Bank under HM854717 Accession Number. 
Sensitive (MHOM/IR/2002/Mash2) strain of 
L. tropica was kindly provided by the Center 
for Research and Training in Skin Diseases 
and Leprosy (Tehran, Iran). The parasite was 
cultured in RPMI-1640, supplemented with 
penicillin (100 IU/mL), streptomycin (100 
μg/mL), and 15% heat-inactivated fetal calf 
serum (FCS). 
 
Preparation of murine macrophages 
In this study, murine macrophage cells were 
collected from male BALB/c mice (5-8 weeks 
old) by injecting 3-5 mL of cold RPMI-1640 
medium into mouse peritoneal cavity and aspi-
rated macrophages were washed twice and 
resuspended in RPMI-1640 medium. The ex-
perimental procedures carried out in this study 
complied with the guidelines of the Kerman 
University of Medical Science (Kerman, Iran) 
for the care and use of laboratory animals. 
 
Leishmanicidal activity against pro-
mastigotes 
Leishmanicidal activity of Se NPs on pro-
mastigote forms of sensitive and glucantime-
resistant strains of L. tropica was evaluated by 
colorimetric cell viability MTT assay using the 
method described by Mahmoudvand et al. 
(20). Initially, 100 μL of the promastigotes 
(106cells/ mL) harvested from logarithmic 
growth phase was added into a 96-well micro-
titer plate. Then 100 μL of different concen-
trations of Se NPs alone (0-25 μg/mL) or MA 
alone (0-25 μg/mL) and along with Se NPs (2 
μg/mL) was added to each well and incubated 
at 25°C ± 1°C for 72 h. After incubation 10 
μL of MTT solution (5 mg/mL) was added 
into each wells and were incubated at 25°C for 
4 h. Promastigotes cultured in complete medi-
um with no drug used as positive control, and 
complete medium with no promastigotes and 
drugs as blank. All experiments were repeated 
in triplicate. Finally, absorbance was measured 
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by an ELISA reader (BioTek-ELX800) at 490 
nm. We also calculated the 50% inhibitory 
concentrations (IC50 values) by Probit test in 
SPSS software. 
 
Effects on intramacrophage amastigotes 
For evaluation of antileishmanial activity of 
Se NPs on L. tropica intracellular amastigotes, 
murine macrophages collected from male 
BALB/c mice were used according to the 
method described elsewhere (21). Briefly, 
1cm2 cover slips were placed in the wells of 4-
chamber slides (Lab-Tek, Nalge Nunc Inter-
national NY, USA) and then 200 μL of the 
murine macrophages (106cells/mL) was placed 
in each well. After 2 h, promastigotes of each 
strain were added to each well and were incu-
bated at 37°C in a CO2 incubator (5% CO2 
and 95% relative humidity). After 24 h free 
parasites were removed by washing with 
RPMI-1640 medium and infected macro-
phages were treated with different concentra-
tions of Se NPs alone (0-50 μg/mL) or MA 
alone (0-50 μg/mL) and along with Se NPs (5 
μg/mL) for 72 h. Finally, dried slides were 
fixed with methanol, stained by Giemsa and 
studied under a light microscope. In this step, 
macrophages containing amastigotes without 
treatment and macrophages with no parasite 
and treatment were considered as positive and 
negative controls, respectively. Antileishmanial 
activity of treatments and the mean number of 
amastigotes were evaluated by counting the 
number of amastigotes in 100 macrophages 
(9). All experiments were carried out in tripli-
cate. In addition, the IC50 values were calcu-
lated by Probit analysis. 
 
Inhibition of infection in macrophage cells 
The inhibitory effect of the Se NPs on the 
Leishmania invasion of macrophages was in-
vestigated in promastigote forms of sensitive 
and Glucantime-resistant strains of L. tropica. 
Firstly, promastigotes in the stationary phase 
were pre-incubated with Se NPs (1 μg/mL) 
for 1 h at 37°C. In the next step, pro-
mastigotes were washed with RPMI-1640 me-
dium and further incubated for 4 h with mu-
rine macrophages at a ratio of 10 Leishmania 
per 1 macrophage. After washing, the macro-
phages were fixed with methanol, stained by 
Giemsa and studied by a light microscope and 
frequency of infected macrophages was meas-
ured by counting 100 macrophages (22). 
 
Hemolytic activity of Se NPs 
The hemolytic activity was evaluated by in-
cubating the various concentrations of Se NPs 
(0- 200 μg/mL) with a 5% O+ human red 
blood cells (RBC) suspension for 1 h at 37°C. 
The erythrocyte suspension was centrifuged 
(1000 g for 10 min), and cell lysis was deter-
mined spectrophotometrically (540 nm), as 
described (23). The absence (blank) or 100% 
presence of hemolysis (positive control) was 
determined by replacing the Se NPs for an 
equal volume of PBS 1x or distilled water, re-
spectively. The results were calculated by the 
percentage of hemolysis compared to the neg-
ative and positive controls. 
 
Statistical analysis 
SPSS Software ver. 17 (SPSS Inc., Chicago) 
was used for data entry and statistical analysis 
and the differences between groups were de-
termined by using one way analysis of variance 
(ANOVA) test. Moreover, to compare the 
IC50 values of Se NPs and control drug t-test 
performed. P-value of less than 0.05 was con-
sidered statistically significant. 
 
Results  
 
Characterization of Se NPs  
Figure 1 shows the TEM image of Se NPs. 
The TEM micrograph clearly illustrates indi-
vidual Se NPs with a small amount of aggre-
gation and the NPs have a spherical shape. 
Size distribution measured from manual 
counting of 400 individual particles from dif-
ferent TEM images showed that the size of 
nanoparticles was 80–220 nm and NPs with 
the size of 105 to 130 nm had the most fre-
quency. The XRD pattern of Se NPs showed 
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the presence of broad peaks without any clear 
lattice parameters (results not shown).Thus 
the obtained Se NPs are amorphous. 
 
 
 
Fig. 1: Transmission electron micrograph of the 
purified selenium nanoparticles (Se NPs) synthe-
sized by Bacillus sp. MSh-1 
Leishmanicidal activity against pro-
mastigotes  
In contrast to controls, various concentra-
tions of Se NPs alone or combined with MA 
significantly inhibited (P<0.05) the growth 
rate of promastigotes of both strains in a 
dose-dependent manner. The measured IC50 
values of Se NPs for sensitive and glucantime-
resistant strains were 2.7 and 3.6  μg/mL, re-
spectively. Similarly, the IC50 values of MA 
plus Se NPs for sensitive and glucantime-re-
sistant strains were 1.5 and 2.8 μg/mL, respec-
tively. In contrast, the IC50 values of MA for 
sensitive and glucantime-resistant strains were 
11.6 and 43.6 μg/mL, respectively, which are 
significantly (P<0.05) higher than the meas-
ured IC50 values for Se NPs alone and along 
with MA against both strains of L. tropica, re-
flecting more effective leishmanicidal effects 
of Se NPs alone and along with MA as com-
pared with MA alone upon promastigotes of 
both strains of L. tropica (Table 1). 
 
Table 1: Comparison of the mean IC50 values of meglumine antimoniate (MA), biogenic selenium nanoparti-
cles (Se NPs) alone and combined with MA upon the growth rate of promastigote and amastigote forms of 
sensitive and glucantime-resistant strains of L. tropica. Data are expressed as the mean ± SD (n = 3) 
 
IC50 (μg/mL) Chemicals 
Amastigotes Promastigotes  
RS SS RSb SSa  
151 ± 4.35 39.2 ± 2.52 43.6 ± 3.05 11.6 ± 1.55 MA 
7.3 ± 1.15 6.4 ± 2.01 3.6 ± 1.4 2.7 ± 0.3 Se NPs  
5.7 ± 1.15 3.3 ± 1.0 2.8 ±1.15 1.5 ± 0.43 MA plus Se NPs  
a: sensitive strain of L. tropica/b: glucantime-resistant strain of L. tropica 
 
 
Leishmanicidal effects on amastigotes  
Biogenic Se NPs prepared by Bacillus sp. 
MSh-1 indicated a potent antileishmanial ef-
fect especially in combination with MA to the 
intramacrophage amastigotes of both strains 
after 72 h exposure. It could be observed that 
the anti-amastigote effects of Se NPs was 
based on a dose-dependent response, so that 
Se NPs induced the inhibition of the growth 
rate of amastigote forms within macrophage 
cells at concentrations of higher than 5 
μg/mL when the mean number of 
amastigotes in each macrophage was assessed. 
However, when Se NPs combined with MA, 
the proliferation rate of amastigotes was sig-
nificantly reduced (P<0.05) at concentration 
of higher than 2.5 μg/mL for both indices of 
amastigote-macrophage model as compared 
with positive control. The measured IC50 val-
ues for Se NPs alone, MA alone and along 
with Se NPs against this parasitic form of sen-
sitive and glucantime-resistant strains of L. 
tropica were also shown in Table 1.  
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Inhibition of infection in macrophages 
 Assessment of infectivity rate of the sensi-
tive and glucantime-resistant strains of L. trop-
ica promastigotes to the murine macrophage 
before and after treatment with the Se NPs 
indicated that promastigotes of both strains of 
L. tropica treated with no Se NPs were able to 
infect 78% and 81% of the macrophages, re-
spectivelly. When promastigotes of both 
strains were pre-incubated with 1 μg/mL Se 
NPs for 2 h, they were able to infect only 16.3 
and 21.6% of the murine macrophage cells 
respectively, in turn presenting reductions in 
their infectivity in the order of 79.3 and 73.3% 
for sensitive and glucantime-resistant strains 
of L. tropica, respectively (Table 2). Based on 
these results, it can be deduced that pre-treat-
ment with the Se NPs was able to inhibit sig-
nificantly the infection of Leishmania pro-
mastigotes into the murine macrophages. 
 
Table 2: Inhibition of the infection in murine macrophages after treatment of sensitive and glucantime-
resistant strains of L. tropica promastigotes with the meglumine antimoniate(MA) and biogenic selenium nano-
particles (Se NPs). Data are expressed as the mean ± SD (n = 3) 
 
a: sensitive strain of L. tropica/b: Glucantime-resistant strain of L. tropica 
 
Hemolytic activity of Se NPs 
In evaluation of the hemolytic activity of Se 
NPs in O+ human RBCs, it could be seen no 
significant hemolytic activity at concentations 
lower than 25 μg/mL, As compared with the 
positive control. However, Se NPs at concen-
trations of 25 and higher indicated significant 
hemolytic activity in O+ human RBCs. 
  
Discussion   
 
Leishmaniasis is a major public health prob-
lem in many countries around the world. The 
first line drugs, antimonials have been used for 
more than 65 years. In addition, other new 
drugs approved for the oral treatment of ACL 
and/or ZCL including miltefosine, ketocona-
zole, itraconazole, allopurinole, dapsone, and 
different physical therapies such as cryother-
apy, surgical excision and heat are used (24-
26). At present, the use of these drugs are lim-
ited due to high cost, toxicity, long-term 
treatment, partial effectiveness and the emer-
gence of drug resistance (6-8). Recently, com-
bination therapies with intra-lesional or sys-
temic MA have been used for CL with differ-
ent drugs, such as verapamil, allopurinol and 
imiquimod that proved their synergistic effects 
along with MA or sodium stibogluconate in 
treatment of CL (9, 11). Furthermore, in re-
cent years, the use of nano drugs such as silver 
and gold nanopaticles to treat CL has been-
proven (27, 28).  
Selenium compounds have extensive appli-
cations in medicine as anticancer, antioxidant 
and antimicrobial agents and their effects are 
related to immune system (6-8). Nanoparticles 
have been used for various medical applica-
tions due to their small nanoscale sizes and 
their high surface-to-volume ratios that allow 
more active sites for interacting with biological 
molecules such as microorganisms and other 
bioactive entities. On the other hand, nano-
particles provide a valuable feature to pene-
trate easily tissues with tumors and can elimi-
nate cancerous cells without affecting the 
Infectiveness 
Reduction 
)%( 
Percentage of infected 
macrophages by 
treated promastigotes 
Percentage of infected 
macrophages by 
non-treated promastigotes 
 
Chemicals 
RS SS RS SS RSb SSa  
       
66.3 56 27.3 ± 2.15 34.6 ± 2.52 81 ± 3.6 78.6 ± 3.05 MA 
73.3 79.3 21.6 ± 2.52 16.3 ± 2.15 81 ± 3.6 78.6 ± 3.05 Se NPs  
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normal tissues (6-8). Se NPs are able to reduce 
the development of HIV progression to AIDS 
and can inhibit the progression of hepatitis B 
and C to liver cancer (13, 29-31). In addition, 
it has been shown that Se NPs inhibit the 
growth of Staphylococcus aureus and pathogenic 
Escherichia coli (16, 17).  
In this study, we evaluated the antileishma-
nial activity of biogenic Se NPs alone and in 
combination with MA against sensitive and 
glucantime-resistant L. tropica on in vitro. The 
main reason for selection of this species was 
that the control of L. tropica is only by 
chemptherapy, which makes it vulnerable to 
resistance (7, 8). In the promastigote stage, the 
mean optical density (OD) and consequently 
IC50 values for Se NPs along with MA against 
promastigote forms of both strains of L. tropi-
ca were lower than the Se NPs or MA alone.  
This showed that the Se NPs were toxic to 
promastigotes and it might cause some mor-
phological and biochemical changes such as 
DNA fragmentation during apoptotic cell 
death in the parasite as previously demonstrat-
ed elsewhere (19). Similarly, the Se NPs signif-
icantly reduced the viability of intramacro-
phage amastigotes of both strains and the 
mean infection rate of macrophages a com-
pared with each drug alone. Furthermore, we 
demonstrated that the infection rate of mac-
rophages significantly decreased when pro-
mastigotes of both strains of L. tropica were 
pre-treated with Se NPs. 
 It has previously been proven that some 
protozoan including Trypanosoma and Leishma-
nia and other higher microorganisms, need 
trace amounts of Se ions (32). However, we 
showed higher in vitro concentrations of Se 
NPs were toxic for both stages of sensitive 
and glucantime-resistant strains of L. tropica. 
Also in the present study it is found that pro-
mastigote forms were more susceptible to Se 
NPs (alone or in combination with MA) than 
amastigote forms. This difference in suscepti-
bility of promastigote and amastigote stages 
against various concentrations of Se NPs 
might be related to structural, biochemical and 
morphological features (9, 33) and also other 
factors, including the phagolysosomal mem-
brane of the macrophage, which reduce the 
entry of Se NPs into the macrophage cells and 
decrease the concentrations of Se NPs around 
the intramacrophage amastigotes (12, 19). In 
this study we reported that Se NPs at lower 
concentration had no hemolytic effect, where-
as, the higher concentration of Se NPs 
showed more hemolytic effect on O+ human 
red blood cells.  
Similar results were found by Beheshti et al. 
and Shakibaie et al. that demonstrated Se NPs 
at the low doses had no cytotoxic effects and 
could be considered safe (12, 19). Recently 
Shakibaie et al. have found that no bio-
chemical changes were observed from the 
orally administration of 2.5, 5 and 10 mg/kg 
of Se NPs to male mice for two weeks, but a 
dose of 20 mg/kg of Se NPs indicated signs 
of toxicity including lower body weight and 
changes in clinical chemistry and hematologi-
cal parameters (34). Moreover, they showed 
that the biogenic Se NPs were less toxic than 
synthetic Se NPs and much less (26-fold) toxic 
than the SeO2.  
 
Conclusion  
 
High potency and synergistic effect of Se 
NPs alone and combined with MA in inhibit-
ing growth of promastigote and amastigote 
stages of sensitive and glucantime-resistant 
strains of L .tropica. The results of this study 
suggest a first step in the search of Se NPs as 
a new antileishmanial agent. Further clinical 
studies are required to investigate the activity 
of the Se NPs as a new therapeutic agent 
against leishmaniasis. 
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